Nanobiotix S.A. American Depositary Shares (NBTX) Stock Price

NBTXStock

$41.51+337.69%52W

Market Cap$2.11B

P/E—

PEG Ratio—

Div yield—

Beta-0.32

NBTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)40.96%

Price vs S&P 500 (4W)0.36%

VGM Score47.70

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)9.50x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.82

Price vs S&P 500 (YTD)64.16%

Net Profit Margin (TTM)-80.84%

EPS (TTM)$-0.58

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$-0.58

Revenue Growth (5Y)258.58%

EPS (Annual)$-0.58

ROI (Annual)-67.39%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-122461.58%

Cash / Share (Quarterly)$1.27

Revenue Growth QoQ (YoY)304.48%

ROA (Last FY)-35.36%

Revenue Growth TTM (YoY)-80.24%

EBITD / Share (TTM)$-0.24

ROE (5Y Avg)-124.29%

Operating Margin (TTM)-38.11%

Cash Flow / Share (Annual)$-0.82

P/B Ratio936.97x

P/B Ratio (Quarterly)65.40x

Net Income / Employee (Annual)$-288,246

EV / Revenue (TTM)58.08x

Net Interest Coverage (TTM)-0.89x

ROA (TTM)-42.44%

EPS Incl Extra (Annual)$-0.58

Current Ratio (Annual)1.09x

Quick Ratio (Quarterly)1.05x

3-Month Avg Trading Volume0.19M

52-Week Price Return337.69%

Revenue / Employee (TTM)$356,631

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)56.64x

Asset Turnover (Annual)0.44x

52-Week High$55.62

Operating Margin (5Y Avg)-133512.98%

EPS Excl Extra (Annual)$-0.58

CapEx CAGR (5Y)38.54%

Tangible BV CAGR (5Y)11.42%

26-Week Price Return53.09%

Quick Ratio (Annual)1.05x

13-Week Price Return-3.45%

Total Debt / Equity (Annual)1.60x

Current Ratio (Quarterly)1.09x

Enterprise Value$2.01B

Revenue / Share Growth (5Y)211.90%

Asset Turnover (TTM)0.53x

Book Value / Share Growth (5Y)-6.95%

Revenue / Employee (Annual)$356,631

Pretax Margin (Annual)-80.83%

Cash / Share (Annual)$1.27

3-Month Return Std Dev58.17%

Net Income / Employee (TTM)$-288,246

ROE (Last FY)-175.45%

Net Interest Coverage (Annual)-0.89x

EPS Basic Excl Extra (Annual)$-0.58

Receivables Turnover (TTM)11.60x

Total Debt / Equity (Quarterly)23.58x

EPS Incl Extra (TTM)$-0.58

Receivables Turnover (Annual)11.60x

ROI (TTM)-75.47%

P/S Ratio (TTM)56.64x

Pretax Margin (5Y Avg)-122447.02%

Revenue / Share (Annual)$0.72

Tangible BV / Share (Annual)$0.90

Price vs S&P 500 (52W)317.21%

Year-to-Date Return75.08%

5-Day Price Return-3.12%

EPS Normalized (Annual)$-0.58

ROA (5Y Avg)-64.07%

Net Profit Margin (Annual)-80.84%

Month-to-Date Return1.25%

Cash Flow / Share (TTM)$-1.91

EBITD / Share (Annual)$-0.24

Operating Margin (Annual)-38.11%

LT Debt / Equity (Annual)1.13x

ROI (5Y Avg)-68.91%

LT Debt / Equity (Quarterly)16.13x

EPS Basic Excl Extra (TTM)$-0.58

P/TBV (Quarterly)65.43x

P/B Ratio (Annual)9.50x

Pretax Margin (TTM)-80.83%

Book Value / Share (Annual)$0.90

Price vs S&P 500 (13W)-6.75%

Beta-0.32x

Revenue / Share (TTM)$0.72

ROE (TTM)-300.48%

52-Week Low$8.12

vGradeF

gGradeB

mGradeB

vgmGradeC

NBTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
NBTXNanobiotix S.A. American Depositary Shares	F	B	B	$41.51
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Nanobiotix S.A. American Depositary Shares

Nanobiotix SA is a clinical-stage biotechnology company developing proprietary nanotechnology to enhance the effectiveness of cancer radiotherapy. Its NanoXray platform amplifies radiation effects within tumor cells without increasing exposure to surrounding healthy tissue. The company's lead candidate, NBTXR3, is being evaluated for cancer immunotherapy applications.